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Abstract 
 
Plasma fibrinogen includes DQDOWHUQDWLYHO\VSOLFHGȖ-chain YDULDQWȖ¶ZKLFKPDLQO\H[LVWVDVD
KHWHURGLPHU Ȗ$Ȗ¶ and has been associated with thrombosis. We tested Ȗ$Ȗ¶ fibrinogen-red 
blood cells (RBCs) interaction using atomic force microscopy-based force spectroscopy, 
magnetic tweezers, fibrin clot permeability, scanning electron microscopy and laser scanning 
confocal microscopy. Data reveal higher work necessary for RBC-RBC detachment in the 
presence of Ȗ$Ȗ¶ rather than Ȗ$Ȗ$ fibrinogen. Ȗ$Ȗ¶ fibrinogen-RBCs interaction is followed by 
changes in fibrin network structure, which forms an heterogeneous clot structure with areas of 
denser and highly branched fibrin fibers. The presence of RBCs also increased the stiffness of 
Ȗ$Ȗ¶fibrin clots which are less permeable and more resistant to lysis WKDQȖ$Ȗ$ clots.  
The modifications on clots promoted by RBCs-Ȗ$Ȗ¶fibrinogen interaction could alter the risk 
of thrombotic disorders. 
 
Keywords: cell adhesion, atomic force microscopy, magnetic tweezers, fibrin clot Ȗ¶
fibrinogen. 
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
3 
 
Background 
 
Fibrinogen is a 340 kDa homodimeric plasma glycoprotein, composed of three pairs of 
polypeptide chains, GHQRWHG$Į%ȕDQGȖ, linked together by 29 disulphide bonds1. A common 
variant of the fibrinogen is produced by alternative splicing of m51$RIWKHȖ-FKDLQFDOOHGȖ¶ 
fibrinogen2. 7KH Ȗ¶ LVRIRUP has a substitution of the final 4 carboxyl-terminal amino acid 
residues (AGDV) of the prevalent Ȗ$-chain with a different 20-amino acid residue sequence 
(VRPEHPAETEYDSLYPEDDL), which includes a high proportion of negatively charged 
residues and two sulfated tyrosines. This variant accounts for 8-15% of all plasma fibrinogen, 
ODUJHO\LQWKHIRUPRIWKHKHWHURGLPHUȖ$Ȗ¶ZKLOHWKHKRPRGLPHUȖ¶Ȗ¶DFFRXQWVIRUOHVVWKDQ
of total plasma fibrinogen3. Ȗ¶ fibrinogen has distinct biochemical and biophysical properties 
WKDW GLVWLQJXLVK LW IURP WKH PRUH FRPPRQ Ȗ$ LVRIRUP4, 5, 6. Studies have highlighted that 
DEQRUPDO SODVPD OHYHOV RI Ȗ$Ȗ¶ ILEULQRJHQ are associated with thrombotic diseases, such as 
coronary artery disease7, myocardial infarction8 and stroke9. EOHYDWHGOHYHOVRIȖ¶ fibrinogen in 
patients with cardiovascular disease (CVD) were independent of the total plasma fibrinogen 
concentration7. This could indicate WKDW WKH SURSRUWLRQ RI Ȗ¶ variant in plasma may be a risk 
factor for cardiovascular pathologies. However, reduced concentrations have been associated 
with microangiopathy syndrome10 and deep vein thrombosis11. Studies by Appiah et al. did not 
VXSSRUW WKH K\SRWKHVLV WKDW Ȗ¶ ILEULQRJHQ LQIOXHQFHV &9' HYHQWV WKURXJK LWV SUothrombotic 
properties. Rather, Ȗ¶ ILEULQRJHQ FRQFHQWUDWLRQV seem to reflect general inflammation that 
DFFRPSDQLHVDQGPD\FRQWULEXWHWRDWKHURVFOHURWLF&9'LQVWHDGRIȖ¶ILEULQRJHQEHLQJDcausal 
risk factor12. In addition to this, Walton et al. fouQG WKDW HOHYDWHG OHYHOV RI Ȗ$Ȗ$ ILEULQRJHQ
promoted arterial thrombosis in vivo ZKHUHDV Ȗ$Ȗ¶ fibrinogen did not13. 1HYHUWKHOHVV DV Ȗ¶
chain modulates clot formation in vitro, further studies are required to elucidate its functional 
properties and its possible relationship with bleeding disorders or thrombosis.  
The formation of a thrombus and subsequent impairment of blood flow to vital organs are the 
immediate cause of CVD events14. The architecture of the clot network affects clot stability, 
particularly its viscoelastic or mechanical properties and fibrinolytic characteristics15, 16. These 
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aspects can determine if the clot is broken down by fibrinolysis or if it will lead to occlusion or 
embolization17. Other studies have indicated the clinical relevance of fibrin clot structure. It has 
been shown that tightly packed and rigid clots with thinner fibers and low porosity are less 
susceptible to the action of thrombolytic agents18, 19, and a prolonged clot lysis time has been 
associated with CVD events20. Several studies KDYH VKRZQ WKDW FORWV SURGXFHG IURP Ȗ$Ȗ¶
fibrinogen have a different structure and behave differently from Ȗ$Ȗ$ clots4, 5, 6. Fibrin clots 
IRUPHG LQ WKH SUHVHQFH RI WKH ILEULQRJHQ Ȗ¶ variant are more resistant to fibrinolysis, due to 
reduced binding of plasminogen and tissue plasminogen activator, leading to reduced plasmin 
generation21. FLEULQRJHQ Ȗ¶ YDULDQW LV DVVRFLDWHG ZLWK D KHWHURJHQHRXV QRQ-uniform clot 
structure, ZLWK PRUH EUDQFK SRLQWV WKDQ FORWV IRUPHG E\ Ȗ$ chains6, 22, 23.In addition, J¶
fibrinogen binds to thrombin exosite II24. The bLQGLQJ RI WKURPELQ WR WKH Ȗ¶ FKDLQ KDV EHHQ
reported to modulate thrombin activity, particularly towards substrates that require exosite II 
interaction such as coagulation factors FV and FVIII (but not those dependent on exosite I 
interactions, e.g. fibrinogen and factor FXIII), which may influence clot structure6. However, 
some of WKH HIIHFWV RI Ȗ¶ fibrinogen on clot structure have been shown to be independent of 
thrombin, as clots produced with snake venom enzyme ancrod, which cleaves fibrinopeptide A 
from fibrinogen but not fibrinopeptide B, show similar structural abnormalities as those 
produced with thrombin22. On the other hand, it has been shown that the high affinity binding of 
WKURPELQ WR Ȗ$Ȗ¶-fibrin protects thrombin from inhibition by antithrombin, raising the 
SRVVLELOLW\WKDWȖ$Ȗ¶-fibrin serves as a scavenger and reservoir for thrombin in the clot25. 
Fibrinogen is thought to contribute to CVD, not only through altering the fibrin network 
structure, but also through several other mechanisms, such as promoting red blood cell (RBC) 
aggregation26. Although several studies on isolated fibrin clots have been performed, in vitro 
experiments using fibrin blood clots containing RBCs are scarce in the literature. RBCs play a 
role in blood coagulation by increasing blood viscosity, which is associated with propensity for 
clot formation27. RBCs have been shown to interact specifically with fibrinogen, with ca.20,000 
binding sites per RBC and a dissociation constant, Kd, of approximately 1.3 µM28. We have 
identified a specific receptor for fibrinogen on the surface of RBCs29, 30, 31.  
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Despite their significance in thrombosis and hemostasis, relatively few studies have been 
conducted to describe the effects of RBCs on blood clot structure, particularly with different 
fibrinogen variants. One complication of studying RBC-rich thrombi is that incorporation of 
RBCs into a thrombus seems uncontrolled and variable. This scarcity may also be, in part, due 
to the fact that the presence of RBCs in a clot often interferes with the techniques available to 
monitor clot structure32.  
The present study aimed to investigate, through atomic force microscopy-based force 
spectroscopy, the adhesion of RBCs in the presence of Ȗ$Ȗ$ RU Ȗ$Ȗ¶ fibrinogen variants. 
Moreover, we aimed to understand the effect of RBC-Ȗ$Ȗ¶ fibrinogen interactions on fibrin clot 
structure, properties and function through scanning electron microscopy, laser scanning 
confocal microscopy, magnetic tweezers and permeability studies.  
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Methods 
 
3XULILFDWLRQRIȖ$Ȗ$DQGȖ$Ȗ¶ILEULQRJHQ 
TKH Ȗ$Ȗ$ DQG Ȗ$Ȗ¶ ILEULQRJHQ YDULDQWV ZHUH purified from human plasminogen-depleted 
fibrinogen using anion-exchange chromatography (Millipore, Billerica, MA) as previously 
described22, 23. Detailed description of the method can be found in Supplementary Material.  
 
Human RBCs isolation 
Blood from healthy donors was obtained, with written informed consent, at the Instituto 
Português do Sangue e da Transplantação (IPST, Lisbon) and at the University of Leeds. This 
study was approved by the joint Ethics Committee of Faculdade de Medicina da Universidade 
de Lisboa and Centro Hospitalar Lisboa Norte, and by the University of Leeds Medical School 
Ethical Committee. RBCs were isolated through standard procedures29, 30, 31. 
 
Atomic force microscopy (AFM) ± Cell-Cell adhesion 
AFM studies were performed on a NanoWizard II atomic force microscope with a CellHesion 
200 module (JPK Instruments, Berlin, Germany), mounted on an Axiovert200 inverted optical 
microscope (Zeiss, Jena, Germany). RBCs were attached to tipless cantilevers through the 
functionalization with concanavalin A (for details see Supplementary Material). RBCs on the 
substrate were adhered to poly-L-lysine coated glass slides. RBC-RBC adhesion was measured 
in the presence of different fibrinogen variant concentrations, from 0 to 1.0 mg/ml. Detailed 
description of the method can be found in Supplementary Material. 
 
Magnetic tweezers 
To examine the viscoelastic properties of the fibrin clots, magnetic tweezers were used. The 
magnetic microrheometer operates by applying a force of 40 pN to a 4.5 µm superparamagnetic 
bead (Dynabeads M-450 Epoxy, Invitrogen, Paisley, UK) using a magnetic field gradient 
generated by four electromagnets in 2D directions. The device was used coupled with an 
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Olympus IX71 inverted microscope (Olympus, UK) incorporating an ultralong working 
objective (40× magnification) and a CCD camera. Particle tracking, electromagnet control and 
image analysis were performed in real time using custom written Labview 7.1 software 
(National Instruments, Newbury, UK). Fibrin clots were formed with and without RBCs. The 
viscoelastic properties were measured using the procedure of Evans et al.337KHSDUDPHWHUV*¶
*¶¶DQG7DQįZHUHFDOFXODWHG at a frequency of 0.1 Hz. The displacement of 8 random magnetic 
beads was measured per sample, and each sample was studied at least in triplicate. Please find 
detailed description in Supplementary Material. 
 
Fibrin clot permeability 
To study the clot permeability, samples were prepared in triplicate, according to the 
standardized protocol published by the Fibrinogen and FXIII Subcommittee of the International 
Society on Thrombosis and Hemostasis (ISTH)34. Purified fibrinogen samples (final 
concentration of 1 mg/ml) were incubated with 1 U/ml human thrombin (Calbiochem, 
Nottingham, UK) and 2.5 mM CaCl2. Samples were placed in mechanically scratched open 
clotting tips for 120 min, at room temperature, in a humidity chamber. A detailed description of 
the method can be seen in Supplementary Material.  
 
Scanning electron microscopy 
Scanning electron microscopy (SEM) was used to further investigate the structure of clots 
formed with ȖAȖA and ȖAȖƍILEULQRJHQ in the presence or in the absence of RBCs.  
Clots were generated by adding 100 µl of ȖAȖA and ȖAȖ¶ fibrinogen variants (final 
concentration of 1 mg/ml) to 10 µl of activation mixture (human thrombin 1 U/ml and 10 mM 
CaCl2, final concentrations, in TBS (50 mM Tris, 100 mM NaCl, pH 7.5)). All details of the 
procedure are described in Supplementary Material.  
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Laser scanning confocal microscopy 
Fibrin clots were prepared according the procedure described in Supplementary Material. Three 
random areas of the clot were visualized under higher magnification.  ȝP Rptical z-stacks 
were obtained and projected into 2D images. In order to obtain 3D images of the fibrin clots, 40 
ȝP z-stacks were also performed. Confocal microscopy was also used to assess, in real time, the 
rate of fibrinolysis following the procedure also described in Supplementary Material. 
 
Statistical Analysis 
Descriptive statistics are given as mean ± standard error of mean (SEM). Unpaired Student¶s t-
test was used for statistical analysis of comparisons between two groups. Non-parametric 
analysis was also performed in cell-cell adhesion data, applying the Mann Whitney U test. P-
values below 0.05 were considered to indicate statistical significance. Statistical analyses were 
performed using GraphPad Prism 5 (La Jolla, CA, USA). 
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Results 
 
RBC-RBC adhesion is altered in the presence of fibrinogen variants 
Atomic force microscopy experiments were performed to investigate RBC cell-cell adhesion 
and the influence of Ȗ$Ȗ¶ and Ȗ$Ȗ$ fibrinogen variants in the cells adhesion. We evaluated the 
LQWHUDFWLRQ EHWZHHQ 5%&V LQ WKH SUHVHQFH RI GLIIHUHQW FRQFHQWUDWLRQV RI Ȗ$Ȗ$ DQG Ȗ$Ȗ¶
fibrinogen variants, up to1.0 mg/ml, by force-distance retract curves (Figure 1). 
$)0 GDWD VKRZHG WKDW LQ WKH SUHVHQFH RI ORZ FRQFHQWUDWLRQV RI Ȗ$Ȗ¶ fibrinogen, the work 
(thermodynamic parameter corresponding to the area under the curve on a force × distance plot, 
Figure 1B) required to detach one RBC from another was higher than in the presence of the 
VDPH FRQFHQWUDWLRQ RI Ȗ$Ȗ$ fibrinogen (0.87 ± 0.07 fJ vs. 0.55 ± 0.04 fJ, p=0.0275, for 0.1 
mg/ml fibrinogen, and 1.03 ± 0.06 fJ vs. 0.65 ± 0.07 fJ, p<0.0001, for 0.4 mg/ml fibrinogen) 
(Figure 1C). At higher concentrations of fibrinogen variants, statistically significant differences 
between both variants were not observed (IRUPJPOILEULQRJHQI-IRUȖ$Ȗ¶vs. 
I-IRUȖ$Ȗ$p=0.144; for 0.7 mg/ml fibrinogen, I-IRUȖ$Ȗ¶vs. 0.86 ± 
I-IRUȖ$Ȗ$p=0.248)Ȗ$Ȗ$ fibrinogen concentrations showed a clear dose-response for 
interactions with RBCsZKHUHDVȖ$Ȗ¶had a dual effect at low and high concentrations (Figure 
1C). Values of the maximum detachment force (schematically explained in Figure 1B) were 
also calculated. As shown on Figure 1D, statistically significant differences between the values 
of maximum RBC-RBC detachment force LQ WKH SUHVHQFH RI Ȗ$Ȗ¶ RU Ȗ$Ȗ$ ILEULQRJHQ ZHUH
found at all fibrinogen concentrations: for 0.1 mg/ml fibrinogen, 141.8 ± 17.2 pN for Ȗ$Ȗ$vs. 
S1IRUȖ$Ȗ¶p = 0.0279; for 0.4 mg/ml fibrinogen, S1IRUȖ$Ȗ$vs. 
S1IRUȖ$Ȗ¶p < 0.0001; for 0.7 mg/ml fibrinogen, S1IRUȖ$Ȗ$vs. 
170.3 ± 0.95 pN IRUȖ$Ȗ¶, p < 0.0001; and, for 1 mg/ml fibrinogen, S1IRUȖ$Ȗ$
vs.    S1 IRU Ȗ$Ȗ¶ p = 0.0054). With the exception of the data obtained for 0.4 
mg/ml fibrinogen, the values of maximum detachment force obtained for Ȗ$Ȗ$ILEULQRJHQZHUH
always lower than those of Ȗ$Ȗ¶ILEULQRJHQ 
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After the initial maximum detachment force, two types of jumps could be observed on the force 
curves (Figure 1B): jumps preceded by a ramp of force or jumps preceded by a force plateau. 
We considered a membrane tether as a step in force detected after a force plateau of 0.25 µm in 
distance. Jump events were assigned to the unbinding of membrane ligand-receptor interactions 
without a preceding membrane deformation, while membrane tether events corresponded to 
situations where a membrane tether was extruded before the unbinding of the ligand-receptor 
complex (Figure 1B)35. A combination of each of the parameters extracted from the force-
distance curves (maximum detachment force, number of jumps events/curve × mean force of 
jumps and number of membrane tethers events × mean force of tethers) could be considered as 
the value of the work needed to detach one cell from another. Similarly to the values of work 
(Figure 1C), the same profile is observed for the values of force of jumps and membrane tethers 
events with increasing fibrinogen concentrations when comparing both fibrinogen variants As 
depicted in Figure 1E,F, at lower fibrinogen concentrations, jumps and membrane tethers 
displayed higher forces IRU Ȗ$Ȗ¶ ILEULQRJHQ, when comparHG WR Ȗ$Ȗ$ YDULDQW, both for 0.1 
mg/ml fibrinogen (jumps, 68.52 ± 2.42 pN vs. 40.40 ± 0.80 pN, p < 0.0001; membrane tethers, 
79.80 ± 7.06 pN vs. 47.56 ± 3.37 pN, p < 0.0001) and 0.4 mg/ml fibrinogen (jumps, 80.82 ± 
3.45 pN vs. 74.94 ± 3.31 pN, p = 0.0061; membrane tethers, 91.91 ± 6.32 pN vs. 68.08 ± 9.69 
pN, p = 0.0069). Figure 1E,F also shows that, at higher fibrinogen concentrations, similarly to 
the values of work, higher forces of jumps and membrane tethers were measured IRU Ȗ$Ȗ$
fibrinogen, when compared to the Ȗ$Ȗ¶ YDULDQt. This becomes evident at 0.7 mg/ml of 
fibrinogen (jumps, 70.94 ± 4.36 pN vs. 24.01 ± 0.77 pN, p < 0.0001; membrane tethers, 117.75 
± 14.64 pN vs. 36.47 ± 5.13 pN, p < 0.0001) and at 1.0 mg/ml of fibrinogen (jumps, 201.51 ± 
8.54 pN vs. 93.41 ± 2.85 pN, p < 0.0001; membrane tethers, 313.95 ± 58.05 pN vs. 135.51 ± 
7.98 pN, p > 0.05). 
 
RBCs influence Ȗ$Ȗ¶ILEULQclot mechanical properties 
7KH YLVFRHODVWLF SURSHUWLHV RI Ȗ$Ȗ$ DQG Ȗ$Ȗ¶ fibrin clots were examined using a magnetic 
microrheometer and the influence of RBCs was studied. In agreement with previous findings22, 
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wHREVHUYHGWKDWȖ$Ȗ$FORWVZHUHVWLIIHUWKDQ Ȗ$Ȗ¶clots (storage modulus, *¶, 1.076 ± 0.065 Pa 
vs. 0.512 ± 0.051 Pa, respectively; p < 0.0001; Figure 27KHSUHVHQFHRI5%&VLQWKHȖ$Ȗ$ 
fibrin clots did not statistically change their stiffness. On the other hand, a significant increase in 
WKHVWLIIQHVVRIȖ$Ȗ¶ clots was observed in clots with RBCs, when compared to those without 
RBCs (1.220 ± 0.104 Pa vs. 0.512 ± 0.051 Pa, respectively; p < 0.0001). There were no 
significant differences RQVWRUDJHPRGXOXV*¶EHWZHHQȖ$Ȗ$DQGȖ$Ȗ¶FORWVLQWKHSUHVHQFHRI
RBCs; however, there was a trend for the Ȗ$Ȗ¶FORWs WREHVWLIIHUWKDQȖ$Ȗ$FORWs (Figure 2). 
In addition, we observed a statistically significant change on loss tangent (7DQ į comparing 
Ȗ$Ȗ$ clots with RBCs and without RBCs (0.460 ± 0.066 vs. 1.013 ± 0.126, respectively; p = 
0.0008), but only DWUHQGIRUKLJKHU7DQįLQȖ$Ȗ¶ZLWK5%&VWKDQIRUWKLV variant in the absence 
of RBCs (data not shown). 
 
RBCs reduce Ȗ$Ȗ¶ fibrin clot permeability 
To characterize the ILEULQ QHWZRUN RI Ȗ$Ȗ$ DQG Ȗ$Ȗ¶ fibrin with and without RBCs, 
permeability experiments were performed. The results for the Darcy constant (Ks), which 
represent the pore size of the fibrin clot, are shown in Figure 3. 
Importantly, in the presence of RBCs, normalized Ks was higher for Ȗ$Ȗ$ fibrin clots with 
RBCs ((2.44 ± 0.3.1) × 10-9 cm2) than for Ȗ$Ȗ¶ILEULQFORWZLWK5%&V(1.40 ± 0.10) × 10-9 cm2) 
(p = 0.0001). Thus, when comparing clots of both fibrinogen variants with RBCs, the Ȗ$Ȗ¶clots 
were less porous.  
 
RBCs influence ȖAȖ$ and Ȗ$Ȗ¶fibrin clot structure  
Scanning electron microscopy data showed differences between the structures of the fibers 
formed by Ȗ$Ȗ$RU Ȗ$Ȗ¶ILEULQRJHQ (different magnification micrographs from each sample are 
shown in Figure S1 in the supplementary information).  
We next investigated the structure of plasma clots formed in vitro in the presence of RBCs to 
determine the effect that these cells might have on clot structure in vivo. RBCs tended to be 
heterogeneously spread throughout the sample, particularly in clots produced with Ȗ$Ȗ¶fibrin 
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(Figure 4). Upon the addition of 20% RBCs, the structure of the Ȗ$Ȗ¶ clot became more 
heterogeneous, with densely packed fiber regions as well as large holes where more RBCs were 
located (Figure 4 A, C, E). Ȗ$Ȗ¶ILEULQILEHUVwere thinner and the network of the clot showed 
more interconnections with RBCs compared to Ȗ$Ȗ$ ILEHUV. On the micrographs of Figure 4 
(panels B, D and F), it can be noticed that Ȗ$Ȗ¶ILEULQFORWVFRQWDLQed more free fiber ends and 
there were more fiber-to-RBC points of connections, when FRPSDUHG WR Ȗ$Ȗ$ ILEULQ FORWV, 
resulting in ³FOXVWHUHG´ cell arrangements. 
In order to measure the diameter of the fibers, twenty fibers from 25000× magnification images 
were assessed on 2 different clots from each condition and in 3 different zones of the clot. 
Average fiber diameters were smaller LQ Ȗ$Ȗ¶ ILEULQ FRPSDUHG WR the Ȗ$Ȗ$ variant (18.29 ± 
1.32 nm vs. 41.10 ± 1.58 nm, p < 0.0001; Figure 5). The presence of RBCs in the fibrin clot 
caused a decrease of the Ȗ$Ȗ$ ILEHUV diameters compared to the clot without RBCs (41.10 ± 
1.58 nm in the absence of RBCs vs. 35.39 ± 2.46 nm in their presence, p = 0.044) (Figure 5). 
7KHSUHVHQFHRI5%&VRQFORWVZLWKȖ$Ȗ¶ILEHUVGLGQRWstatistically change the diameter of the 
fibers compared to the clots without cells. However, clots with RBCs and SUHSDUHGZLWKȖ$Ȗ¶
fibrinogen led to thinner fibers than those SURGXFHGZLWKȖ$Ȗ$ILEULQRJHQ and RBCs (35.39 ± 
2.46 nm for Ȗ$Ȗ$ vs. 15.23 ± 0.98 QPIRUȖ$Ȗ¶, p < 0.0001; Figure 5).  
 
Increased fibrinolytic resistance of Ȗ$Ȗ¶ILEULQFORWV in the presence of RBCs 
We used laser scanning confocal microscopy to study clot structure and resistance to 
fibrinolysis in the presence and absence of RBCs for each fibrin variant. 
Figure 6 shows representative examples of the confocal micrographs obtained for fiber clots 
made with Ȗ$Ȗ$DQGȖ$Ȗ¶SXULILHGILEULQRJHQ variants. In clots formed with Ȗ$Ȗ$ fibrinogen, 
the area occupied by the fibers seems to be larger (Figure 6A) than for the clots with Ȗ$Ȗ¶
fibrinogen (Figure 6B). However, these differences were not statistically significant. In 
agreement with SEM imaging and with previous studies22, there was a clear difference between 
the structures of Ȗ$Ȗ$DQG Ȗ$Ȗ¶ ILEULQ7KH Ȗ$Ȗ$ fibrin clots were composed of longer and 
straighter fibers than Ȗ$Ȗ¶fibrin clots. The later showed fibers that were shorter and clustered, 
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producing larger pores. However, we did not find differences regarding the fiber density 
FRPSDULQJȖ$Ȗ$ZLWKȖ$Ȗ¶ILEULQ clots (Figure S2). 
Relevant was to study the mLFURJUDSKVRIILEULQFORWVIURPȖ$Ȗ$DQGȖ$Ȗ¶ILEULQRJHQYDULDQWV
in the presence of 2% of RBCs, as shown on Figure 6 (C,D) ,Q WKH SUHVHQFH RI Ȗ$Ȗ$
fibrinogen, the network of the fibers seemed straighter and denser,QFORWVZLWKȖ$Ȗ¶ILEHUV, we 
observed that the fibers were more clustered and the RBCs were more visible. We also studied 
fibrin clots in the presence of 5% and 10% of RBCs by LSCM; however, the high number of 
RBCs did not allow clearly differentiating fibrin fibers from RBCs. Thus, technical limitations 
restricted us to increase the amount of RBCs closer to the physiological range. 
Finally, we studied fibrinolysis of clots made with both fibrinogen variants (Figure 7). In line 
with previous studies21, a significant increase in lysis time was observed for Ȗ$Ȗ¶ compared 
with Ȗ$Ȗ$ fibrin clots (15.82 ± 1.48 min vs. 10.54 ± 0.44 min, respectively; p = 0.0267). 
During the experiment, we observed a non-uniform lysis of the Ȗ$Ȗ¶ fibrin clot, taking more 
time to achieve complete lysis than the Ȗ$Ȗ$ clot (videos in Supplementary information). 
We measured the lysis time for Ȗ$Ȗ$DQGȖ$Ȗ¶FORWVLQWKHSUHVHQFHRIGDWDQRWVKRZQDQG
10% of RBCs. Under these conditions, there were no significant differences in fibrinolysis times 
in the presence of RBCs, when compared to the clots without RBCs. Statistical significance was 
observed in fibrinolysis times for Ȗ$Ȗ$ vs. Ȗ$Ȗ¶ fibrin clots in the presence of RBCs (12.03 ± 
0.49 min vs. 18.30 ± 1.47 min; p = 0.0476). 
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Discussion 
 
In this study, we evaluated the interaction of purified Ȗ$Ȗ¶ and Ȗ$Ȗ$ fibrinogen with RBCs, as 
well as their influence on the structure and function of clots formed with both variants. They 
show a discernible effect of the presence of RBCs on fibrin clot structure and function. To 
pursue this study further, we purified the main component of plasma fibrinogen, Ȗ$Ȗ$, and its 
splice-variant, Ȗ$Ȗ¶. Cell-cell adhesion studies were performed to evaluate the relative roles of 
both fibrinogen variants on the interaction between RBCs. We also evaluated the changes of 
biophysical properties of the clots, by studying their permeability and viscoelastic properties. 
By laser confocal microscopy and scanning electron microscopy, we directly observed the 
effects of RBCs on the architecture of clots IRUPHGIURPȖ$Ȗ¶DQG Ȗ$Ȗ$ILEULQRJHQV.  
$)0GDWDVKRZHGWKDWLQWKHSUHVHQFHRIORZFRQFHQWUDWLRQVRIȖ$Ȗ¶ILEULQRJHQPJPl), 
the force of the binding between two RBCs was higher than with Ȗ$Ȗ$ILEULQRJHQStatistically 
significant differences between both fibrinogen variants at all fibrinogen concentrations were 
obtained for the values of force for the maximum cell-cell detachment, jumps and membrane 
tether events. Although these three parameters contribute to the values of the work necessary to 
completely detach two RBCs, no statistically significant variations were obtained for this 
SDUDPHWHUDWILEULQRJHQFRQFHQWUDWLRQV mg/mL. 
7KXV DW ORZHU ILEULQRJHQ FRQFHQWUDWLRQV Ȗ$Ȗ¶ ILEULQRJHQ ELQGs more promptly to RBCs, 
inducing higher RBC-5%&DGKHVLRQ WKDQȖ$Ȗ$ILEULQRJHQ5%&VDGKHVLRQKDVDFOHDUȖ$Ȗ$
ILEULQRJHQ GRVH UHVSRQVH FXUYH ZKHUHDV Ȗ$Ȗ¶ GLG QRW This could be due to differences in 
fibrinogen variant molecular conformations and net protein electrostatic charge, which could 
lead to different binding affinities at different fibrinogen concentrations. It is known that RBCs 
present sialic acid residues on their surface, contributing to their negative surface charge, which 
induce repulsive electrostatic forces that minimize RBC aggregation under blood flow 
conditions367KHELQGLQJRIWKHPRUHQHJDWLYHO\FKDUJHGȖ¶ILEULQRJen to RBCs may increase 
the overall negative cell surface charge. This may overcome the strong RBC-RBC interactions 
REVHUYHGDW ORZHUȖ$Ȗ¶ILEULQRJHQFRQFHQWUDWLRQE\ORZHULQJFHOO-cell adhesion forces, due to 
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increased electrostatic repulsion. On the othHU KDQG Ȗ$Ȗ$ ILEULQRJHQ ODFNV WKH QHJDWLYHO\
FKDUJHGVHTXHQFHRIȖ¶ chain, leading to an increase of RBC-RBC adhesion upon increasing its 
concentration. 
Previous studies have shown that RBCs influence the viscoelastic properties of the clot32, 37. Our 
evaluation of the viscoelastic properties of the clots UHYHDOHGWKDWȖ$Ȗ$ILEULQFORWVare stiffer 
WKDQȖ$Ȗ¶ILEULQFORWV in the absence of RBCs, in agreement with previous studies on the effect 
RIȖ$Ȗ¶RQFORWVWLIIQHVV22. Our data shows that Ȗ$Ȗ¶FORWVDUHLQKHUHQWO\ZHDNHU. This is likely 
due to differences in fibrin fiber structure. We recently demonstrated WKDW ILEULQRJHQ Ȗ¶ 
influences intrafibrillar structure of fibrin and significantly reduces the average number of 
protofibrils packed within the fibrin fiber, thereby influencing clot stiffness38 ,Q Ȗ$Ȗ$ ILEULQ
clots, more protofibrils are packed within fibrin fibers, which increases the rigidity and the 
viscosity of the clot, ZKHQFRPSDUHGWRȖ$Ȗ¶ILEULQFORWs. In this study, the presence of RBCs 
did not LQIOXHQFH WKH VWLIIQHVV RI WKH Ȗ$Ȗ$ ILEULQ FORWV In Ȗ$Ȗ¶ ILEULQ clots, the presence of 
RBCs resulted in a significant increase in stiffness. This indicates that the combination of Ȗ$Ȗ¶
fibrinogen variant and RBCs may affect clot structure and mechanical properties. The stiffening 
RIWKHȖ$Ȗ¶ILEULQFORWs in the presence of RBCs may be related to rearrangements of protofibril 
packing or significant modifications in clot structure. The imaging by SEM of the clot structure 
in the presence of RBCs, compared to its absence, showed a looser structure in clots produced 
with Ȗ$Ȗ¶ ILEULQRJHQ, which may be more prone to creep, as well as more fiber 
interconnections, which turn the clot more rigid. Our data indicates that RBCs are not a mere 
bystander in blood clot formation. Indeed, other studies have shown that RBCs influence fibrin 
network structure and pore size39, 40. A decrease in the permeability of fibrin clots after the 
addition of RBCs was shown to be proportional to the total RBC surface area and their total 
concentration40. Here, we show that the addition of RBCs promotes the decrease of 
permeability. Importantly, we show that WKHȖ$Ȗ¶FORWVZLWK5%&VZHUHOHVVSRURXVWKDQȖ$Ȗ$
clots with RBCs. This could potentially lead to pro-thrombotic clots, due to a higher resistance 
to fibrinolysis41. In agreement with this, we also found an increase in the lysis time RIȖ$Ȗ¶FORWV
with RBCs, when compared to Ȗ$Ȗ$FORWVZLWK5%&V 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
16 
 
According with previous studies22, 23, SEM and confocal microcopy showed that the clots 
IRUPHGE\Ȗ$Ȗ$DQGȖ$Ȗ¶ILEHUVhave a different structure. The incorporation of RBCs has an 
important impact on fibrin fiber size and in its network structure. Regions of higher and lower 
RBC density were clearly visible in the clots made with Ȗ¶fibrinogen. In the presence of RBCs, 
the Ȗ¶ fibrin clots were more heterogeneous, seeming to form a looser structure when compared 
with the clots of Ȗ$ fibrinogen. These findings are supported by our AFM data. At high Ȗ$Ȗ¶
fibrinogen concentrations, the work necessary to detach two RBCs was the same that the one 
achieved in the presence of Ȗ$Ȗ$ fibrinogen. In agreement with this, the clot might become 
looser, with a higher ability to deform and embolise, eventually blocking a downstream blood 
capillary.  
7KHȖ$Ȗ¶ILEULQFORWVFRQWDLQDODUJHQXPEHURIIUHHILEHUHQGV)LEHUHQGVDUHQRUPDOO\IRXQGDW
low levels in scanning electron micrographs of fibrin clots, and have been suggested to arise 
from early truncation of protofibril formation or lateral aggregation42, 43. It was previously 
proposed that the negative charge RI Ȗ$Ȗ¶ fibrinogen on the D-D interface may disrupt 
oligomerization and, therefore, interrupt the continuous growth of the protofibril, leading to 
highly branched fibers44, 45.  
This study has shown that the incorporation of RBCs into the clot affects fibrin fiber formation. 
RBCs induced thinning of fibers in fibrin clots formed with Ȗ$Ȗ$, but not with Ȗ$Ȗ¶ fibrinogen. 
However, in the presence of RBCs, Ȗ$Ȗ$ILEHUVUHPDLQHGVLJQLILFDQWO\WKLFNHUWKDQȖ$Ȗ¶ fibers. 
Here, ZH FRXOG FRQFOXGH WKDW WKLQQHU ILEULQ ILEHUV VXFK DV Ȗ$Ȗ¶ ILEULQ ILEHUV form highly 
branched networks. We propose that growing fibers surround RBCs, interacting with them 
through an RBC surface receptor. We have already reported the existence of a receptor for 
fibrinogen on RBCs29, 30, 31:RBCs specifically bind fibrin(ogen) via an integrin receptor ZLWKDȕ3 
subunit29, possiblyĮvȕ331. 
Previous studies indicated that fibrin clots with increased fiber branching and resistance to 
fibrinolysis are a risk factor for thrombosis15. Fibrinolysis data showed that the lysis time of a 
Ȗ$Ȗ¶ fibrin clot is longer than for a Ȗ$Ȗ$FORW, as already reported4, 5. The presence of RBCs 
seems to increase the lysis time. However these studies were conducted with a 10% hematocrit, 
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due to technical limitations, considerably below the normal hematocrit of ~40% RBCs. Aleman 
et al. and Tutwiler et al. suggested that RBCs cause direct and complex effects on clot structure 
and stability46, 47. Furthermore, RBCs can support thrombin generation and decrease fibrinolysis, 
suggesting that RBCs may promote fibrin deposition during venous thrombosis46. Other authors 
report the role of RBCs on stabilizing clots based on suppressed tissue plasminogen 
activator(tPA)-induced fibrinolysis in RBC-modified fibrin structures. They also observed, 
using eptifibatide inhibition, that RBCs modulate fibrinolysis through a specific fibrinogen 
receptor41. Collet et al. demonstrated that fibrin clots with a tight fibrin conformation made of 
thinner fibers were lysed at a slower rate than those with a loose fibrin conformation made of 
thicker fibers, although the overall fibrin content remained constant48. ThH Ȗ$Ȗ¶ FORW LV PRUH
KHWHURJHQHRXVWKDQWKHȖ$Ȗ$FORW7KHGHQVHO\SDFNHGDUHDVZLWKILEHUVDQG5%&Vmay impair 
the diffusion of fibrinolytic agents. However, at the same time, there are areas with large holes, 
where their diffusion may be increased. It was suggested that the VORZHUO\VLVRIȖ¶FORWVLVGXH
to delayed fibrinopeptide B release, leading to a delay of plasminogen binding and activation21.  
Some of these findings may provide a mechanism underpinning the epidemiological data 
suggesting that a high UDWLREHWZHHQȖ$Ȗ¶ DQGȖ$Ȗ$ fibrinogen variants may be a risk factor for 
thrombotic disease7, 8, 9. Further studies on the prothrombotic nature of RBCs and on fibrinogen 
variants are necessary to fully understand the contribution of the Ȗ¶ chain and RBCs to different 
etiologies of thrombotic diseases. 
In conclusion, the incorporation of RBCs into a fibrin clot significantly affects the clot structure 
and its mechanical properties. RBCs interact differently with clots made with Ȗ-chain fibrinogen 
splice variants, which may explain some of the cardiovascular clinical associations that have 
been reported with these fibrinogen variants. 
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Figure legends 
 
Figure 1 | AFM cell-cell adhesion data. A) Schematic representation of the adhesion between two RBCs 
(one chemically attached to the cantilever and the other on the poly-L-lysine-treated substrate) in the 
presence of fibrinogen variants. B) Representative force-distance curve with the relevant analyzed 
parameters, namely, work of cell-cell detachment (grey area), maximum detachment force, jumps and 
membrane tethers (insets magnify examples of a jump and a membrane tether event on the force-distance 
curve). C) Work necessary to overcome RBC-RBC adhesion in the presence of different concentrations of 
Ȗ$Ȗ$ RU Ȗ$Ȗ¶ ILEULQRJHQ  p = 0.0275; ***, p < 0.0001). D) Maximum detachment force values to 
detach two RBCs (*, p = 0.0279; **, p= 0.0054; ***, p < 0.0001. E) Jumps and F) membrane tethers 
force data (**, p  0.0069; ***, p < 0.0001) in the presence of each fibrinogen variant or in their absence. 
Values are presented as mean ± standard error of mean (SEM).  
 
Figure 2 | 9LVFRHODVWLFSURSHUWLHVRIWKHSXULILHGȖ$Ȗ$DQGȖ$Ȗ¶ILEULQRJHQFORWV6WRUDJHPRGXOXV*¶
(elastic modulus) data are presented in the presence of 0.5 % RBCs and in the absence of RBCs (***, p < 
IRUȖ$Ȗ$vs. Ȗ$Ȗ¶DQGIRUȖ$Ȗ¶vs. Ȗ$Ȗ¶5%& Fibrinogen concentration was 0.5 mg/ml. Values 
are presented as mean ± SEM. 
 
Figure 3 | Normalized permeability data (normalized in percentage against Ks of each variant 
ZLWKRXW 5%&V LQ WKH SUHVHQFH RI 5%&V IRU ILEULQ FORWV IRUPHG ZLWK SXULILHG Ȗ$Ȗ$ RU Ȗ$Ȗ¶
fibrinogen. Darcy constant, Ks, represents the average size of the pores within the clot (*, p= 0.0319). 
Values are presented as mean ± SEM. 
 
Figure 4 | Scanning electron micrographs of fibrin fiber clots with 20% of RBCs. Fibers were formed 
from 1.0 mg/ml fibrinogen variants Ȗ$Ȗ$ $ & DQG ( DQG Ȗ$Ȗ¶ % ' DQG ) White arrows in A 
indicate the PRUH KRPRJHQHRXV VWUXFWXUH LQ WKH Ȗ$Ȗ$ clot network, when compared with the areas of 
small and large holes, pinpointed by red arrows in B,, associating a more heterogeneous structure to the 
Ȗ$Ȗ¶ FORWV 7KH IUHH ILEHU HQGV DQG WKH ILEHU-to-RBC points of connections are represented as small 
circles, being more frequent for Ȗ$Ȗ¶UHGFLUFOHV in F) WKDQIRUȖ$Ȗ$ZKLWHFLUFOHVLQ(. Magnifications: 
A and B, 2500×; C and D, 5000×; E and F, 25000×. 
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Figure 5 _'LDPHWHUVRISXULILHGȖ$Ȗ$DQGȖ$Ȗ¶ILEULQ ILEHUV LQWKHDEVHQFHRU LQWKHSUHVHQFHRI
20% of RBCs. Fiber diameters were measured from 20 random fibers of each image using a 25000× 
magnification (*, p = 0.0439; ***, p < 0.0001). 
 
Figure 6 | /DVHUVFDQQLQJFRQIRFDOPLFURVFRS\LPDJHVRIILEHUFORWVIRUPHGZLWKSXULILHGȖ$Ȗ$$
DQG&DQGȖ$Ȗ¶ %DQG' ILEULQRJHQDW PJPO ILEULQRJHQFRQFHQWUDWLRQ. Alexa 488-labelled 
fibrin fibers are shown in green. Confocal micrographs of fiber clots with 2% of RBCs formed with 1.0 
PJPORISXULILHGȖ$Ȗ$&DQGȖ$Ȗ¶ fibrinogen (D). Alexa 488-labelled fibrin fibers are shown in green. 
RBCs were labeled with Vibrant DiD cell-labeling solution (red). Z-stack images at 40 µm and 63× 
magnification are shown in panel A and B and Z-stacks images at 20 µm, also with 63× magnification are 
shown in panels C and D. 
 
Figure 7 | Fibrinolysis time rates were assessed by laser scanning confocal microscopy from clots 
IRUPHGZLWKSXULILHGȖ$Ȗ$DQGȖ$Ȗ¶ILEULQRJHQLQWKHDEVHQFHDQGSUHVHQFHRI5%&V. The 
serial time scans were taken with 40× magnification. Values are shown as mean ± SEM (*, p  0.0476). 
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Graphical abstract description 
&RPSDULVRQRIWKHLQWHUDFWLRQEHWZHHQUHGEORRGFHOOV5%&VDQGȖ$Ȗ$RUȖ$Ȗ¶
fibrinogen. Schematic representation of the adhesion forces between two RBCs in the 
SUHVHQFH RI Ȗ$Ȗ¶ ILEULQRJHQ ZKLFK DIIHFWV FORW SURSHUWLHV DQG function. Changes on 
fibrin network structure, decreased fiber diameter, increased fibrinolysis and decreased 
SHUPHDELOLW\ E\ Ȗ$Ȗ¶ ILEULQRJHQ-RBC interactions were encountered. The 
nanotechnology-based approach was essential to understand that the RBCs interact 
GLIIHUHQWO\ ZLWK FORWV PDGH ZLWK Ȗ¶ FKDLQ ILEULQRJHQ VSOLFH YDULDQW LQVWHDG RI WKH
FRPPRQYDULDQWȖ$7KLVPD\H[SODLQVRPHRIWKHFDUGLRYDVFXODUFOLQLFDODVVRFLDWLRQV
WKDWKDYHEHHQUHSRUWHGIRUȖ¶ILEULQRJHQ 
 
 
ACCEPTED MANUSCRIPT
